Reported results
- Q4 revenue of $5.3 billion increased 5.4% as reported and 5.6% FXN.
- Q4 GAAP diluted EPS was $2.52 and adjusted diluted EPS was $4.15.
- FY26 revenue of $19.5 billion increased 4.9% as reported and 3.9% FXN.
- FY26 GAAP diluted EPS was $5.06 and adjusted diluted EPS was $12.70.
- FY26 cash from continuing operations increased 30.0% to $3.6 billion and free cash flow increased 42.5% to $2.9 billion.
Guidance
- FY27 GAAP Revenue Growth: Low single-digit
- FY27 Revenue Growth (FXN): Low single-digit
- FY27 Adjusted Diluted EPS: $13.10 to $13.30
Notes
On February 9, 2026, the company completed the spin-off of its former Biosciences and Diagnostic Solutions business; historical results of this business are reflected as discontinued operations and prior periods have been recast to reflect the reorganization on a continuing operations basis.
Price and volatility reaction
The stock moved +2.1% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -4.8 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 209.19 | 2026-11-04 |
| Close after release | 213.55 | 2026-11-05 |
| Realised move | +2.1% | close to close |
| 30d ATM IV change | -4.8 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.
